These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11765398)

  • 1. Reading between the lines: direct-to-consumer advertising of genetic testing in the USA.
    Hull SC; Prasad K
    Reprod Health Matters; 2001 Nov; 9(18):44-8. PubMed ID: 11765398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-to-consumer marketing of genetic tests for cancer: buyer beware.
    Gray S; Olopade OI
    J Clin Oncol; 2003 Sep; 21(17):3191-3. PubMed ID: 12874271
    [No Abstract]   [Full Text] [Related]  

  • 3. Reading between the lines: direct-to-consumer advertising of genetic testing.
    Hull SC; Prasad K
    Hastings Cent Rep; 2001; 31(3):33-5. PubMed ID: 11478123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Be ready against cancer, now": direct-to-consumer advertising for genetic testing.
    William-Jones B
    New Genet Soc; 2006 Apr; 25(1):89-107. PubMed ID: 17312631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2004 Jul; 53(27):603-6. PubMed ID: 15254451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advertising genetic testing for breast cancer.
    Weber LJ; Bissell MG
    Clin Leadersh Manag Rev; 2004; 18(1):50-1. PubMed ID: 14968755
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and managing hereditary risk of breast and ovarian cancer.
    Frank TS; Critchfield GC
    Clin Perinatol; 2001 Jun; 28(2):395-406. PubMed ID: 11499060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world health services utilisation and outcomes after
    Dossa F; Cusimano MC; Sutradhar R; Metcalfe K; Little T; Lerner-Ellis J; Eisen A; Meschino WS; Baxter NN
    BMJ Open; 2018 Sep; 8(9):e025317. PubMed ID: 30181190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    Gill J; Obley AJ; Prasad V
    JAMA; 2018 Jun; 319(23):2377-2378. PubMed ID: 29800087
    [No Abstract]   [Full Text] [Related]  

  • 13. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk assessment and genetic testing: complexities, conundrums, and community.
    Peshkin BN
    Breast Dis; 2006-2007; 27():1-3. PubMed ID: 17917137
    [No Abstract]   [Full Text] [Related]  

  • 17. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
    Nippert I; Schlegelberger B;
    Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization.
    Mouchawar J; Laurion S; Ritzwoller DP; Ellis J; Kulchak-Rahm A; Hensley-Alford S
    Am J Manag Care; 2005 Oct; 11(10):601-8. PubMed ID: 16232001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1/2 genetic testing in the community setting.
    Chen WY; Garber JE; Higham S; Schneider KA; Davis KB; Deffenbaugh AM; Frank TS; Gelman RS; Li FP
    J Clin Oncol; 2002 Nov; 20(22):4485-92. PubMed ID: 12431973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.